# ulcerative colitis (UC) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 73792
- Completion tokens: 44842
- Reasoning tokens: 21655
- Total tokens: 118634
- API requests reported: 5
- Elapsed seconds: 107.73
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1095.213
- Question handoff seconds: 1109.559
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: MiniMax

---
<think>The user is asking for a comprehensive interpretation of transcriptomic data comparing ulcerative colitis (UC) versus healthy control in colonic mucosal tissue. Let me analyze the data systematically.

Key observations from the data:
1. 100 selected genes total (after deduplication)
2. 40 upregulated, 60 downregulated
3. All genes have FDR ≤ 0.01 (highly significant)
4. The largest fold changes are:
   - Upregulated: SLC6A14 (log2FC=4.85), DUOX2 (4.67), MMP3 (4.64), CHI3L1 (4.59), S100A8 (3.80), CXCL1 (3.46), SERPINB5 (3.29), TRIM29 (2.83), IL1RN (2.88), CXCL2 (2.80), SOCS3 (2.79)
   - Downregulated: AQP8 (-4.42), SLC51A (-3.71), HMGCS2 (-3.45), DPP10-AS1 (-3.40), SLC38A4 (-3.07), GBA3 (-3.00), MEP1B (-2.99), HSD3B2 (-2.77), CYP2B6 (-2.78), ABCG2 (-2.92)

Let me organize the genes into biological programs:

**Program 1: Neutrophil chemotaxis and acute inflammation (UP)**
- CXCL1, CXCL2, CXCL3 (ELR+ CXC chemokines, neutrophil chemoattractants)
- IL1RN (IL-1 receptor antagonist)
- CHI3L1 (chitinase 3-like 1, inflammatory marker)
- S100A8 (calprotectin component)
- LCN2 (lipocalin 2, neutrophil gelatinase-associated lipocalin)
- TIMP1 (tissue inhibitor of metalloproteinases)
- MMP3 (matrix metalloproteinase)
- VNN1 (vanin 1, oxidative stress)
- SOCS3 (suppressor of cytokine signaling)
- IRAK3 (IL-1 receptor associated kinase 3, negative regulator)
- TNC (tenascin C)

**Program 2: Innate antimicrobial defense and barrier dysfunction (UP)**
- DUOX2, DUOXA2 (dual oxidase, ROS production)
- LCN2 (iron sequestration, antimicrobial)
- PI3 (peptidase inhibitor 3, elafin)
- PLA2G2A (phospholipase, antimicrobial)
- REG4 (regenerating islet-derived protein 4)
- S100P (S100 calcium binding protein P)
- CHI3L1
- SERPINB5 (maspin, serine protease inhibitor)
- TGM2 (transglutaminase 2)
- TIMP1
- CD55 (decay accelerating factor, complement regulation)

**Program 3: Epithelial differentiation and absorptive function (DOWN)**
- AQP7, AQP8 (aquaporins, water transport)
- HMGCS2 (mitochondrial ketogenesis)
- SLC16A1 (monocarboxylate transporter MCT1)
- SLC51A (OSTalpha, bile acid transporter)
- ABCG2 (BCRP, drug efflux)
- SLC23A1, SLC23A3 (vitamin C transporters)
- SLC38A4 (amino acid transporter)
- SLC19A3 (thiamine transporter)
- MEP1B (meprin beta metalloprotease)
- GBA3 (beta-glucosidase)
- G6PC (glucose-6-phosphatase)
- HSD3B2 (steroid metabolism)
- CYP2B6, CYP2B7P (drug metabolism)
- DEFB1 (defensin beta 1)
- B4GALNT2 (glycosylation)
- GCNT2 (glycosylation)
- GXYLT2 (glycosylation)
- SCUBE2
- ACSF2 (acyl-CoA synthetase)
- NLN (neurolysin)
- NAT8B, NAT8 (N-acetyltransferase)
- TAT (tyrosine aminotransferase)
- ABCB11 (BSEP, bile salt efflux)
- LIPC (hepatic lipase)

**Program 4: Epithelial-mesenchymal transition and tissue remodeling (UP)**
- PRRX1 (paired related homeobox 1, EMT transcription factor)
- TNC (tenascin C, stromal remodeling)
- CDH3 (P-cadherin, EMT)
- PDPN (podoplanin)
- FILIP1L (filamin A interacting protein)
- TGM2 (transglutaminase)
- MMP3
- SERPINB5
- IGDCC4 (immunoglobulin superfamily DCC subclass member 4)

**Program 5: Immune regulation and adaptive immunity (UP)**
- IL1RN (IL-1 antagonist)
- SOCS3 (negative regulator of cytokine signaling)
- CTLA4 (T cell checkpoint)
- IFI16 (interferon gamma inducible protein 16)
- CD55 (complement regulator)
- VNN1
- IGHV4-31, IGHM, IGHG1, IGH (immunoglobulin heavy chains)
- TRIM29 (viral restriction)

**Program 6: Circadian and metabolic regulation (DOWN)**
- ARNTL2 (BMAL2, circadian)
- HMGCS2 (ketogenesis)
- AQP7, AQP8
- G6PC (gluconeogenesis)

**Program 7: Bile acid and cholesterol metabolism (DOWN)**
- SLC51A (OSTalpha)
- ABCG2 (BCRP)
- ABCB11 (BSEP)
- HMGCS2 (ketogenesis)
- CYP2B6, CYP2B7P
- LIPC

This is a lot - let me consolidate to 5 major programs.

Let me think about this more carefully. The question asks for evidence-grounded and biologically verifiable interpretation. I should:

1. Note that no independent cohort replication is available
2. Distinguish direct evidence from input vs external annotation
3. Be careful with interactions - distinguish physical, regulatory, co-expression, etc.

Let me identify the most coherent programs:

**Program 1: Neutrophil chemotaxis and acute innate inflammation (UP)**
- The CXCL1/CXCL2/CXCL3 cluster is the strongest signal
- All three are ELR+ CXC chemokines that signal through CXCR2
- Network evidence supports CXCR2 as a shared hub
- IL1RN, SOCS3, IRAK3 are negative feedback regulators
- MMP3, CHI3L1, S100A8, LCN2 are neutrophil-associated
- Hallmark: TNFA_SIGNALING_VIA_NFKB, INFLAMMATORY_RESPONSE
- Reactome: Interleukin-17 signaling (KEGG retrieved)

**Program 2: Antimicrobial/oxidative defense and barrier injury (UP)**
- DUOX2/DUOXA2 - hydrogen peroxide generation by epithelial cells
- PI3 (elafin), PLA2G2A (phospholipase A2 group IIA)
- S100P, REG4, CHI3L1
- TGM2 (transglutaminase)
- CD55 (complement)

**Program 3: Loss of epithelial differentiation and absorptive transporters (DOWN)**
- AQP7, AQP8 (water), SLC16A1 (MCT1, lactate/pyruvate), SLC51A (OSTalpha, bile acid), ABCG2 (BCRP), SLC23A1/A3 (vitC), SLC38A4 (amino acid), SLC19A3 (thiamine)
- HMGCS2 (ketogenesis in colonocytes)
- G6PC (gluconeogenesis)
- MEP1B, GBA3 (digestive enzymes)
- DEFB1 (antimicrobial peptide)
- B4GALNT2, GCNT2, GXYLT2 (mucin-type glycosylation)
- GO: Fluid Transport, Water Transport, Carboxylic Acid Transport

**Program 4: Tissue remodeling and EMT (UP)**
- PRRX1, TNC, CDH3, PDPN, FILIP1L, TGM2, MMP3, SERPINB5
- Wound healing response

**Program 5: Bile acid/lipid/drug metabolism (DOWN)**
- SLC51A, ABCG2, ABCB11, HMGCS2, CYP2B6, CYP2B7P, LIPC, HSD3B2
- KEGG: Bile secretion

**Program 6: Adaptive immune signals (UP)**
- IGHV4-31, IGHM, IGHG1, IGH (immunoglobulin heavy chains) - plasma cell/plasmablast signature
- CTLA4 - T cell checkpoint
- TRIM29, IFI16 - innate antiviral/interferon

I think I'll consolidate into 5 programs:
1. Neutrophil/innate inflammation (UP)
2. Antimicrobial/oxidative/IL-17 defense (UP)
3. Epithelial differentiation and absorptive transport loss (DOWN)
4. Tissue remodeling and EMT (UP)
5. Bile acid/lipid metabolism (DOWN)

For key genes, I need to pick 10. Let me think about the most informative ones:
- SLC6A14 (top upregulated, amino acid transporter)
- DUOX2 (top upregulated, ROS)
- MMP3 (matrix metalloproteinase)
- CXCL1, CXCL2, CXCL3 (chemokine cluster)
- CHI3L1 (chitinase)
- S100A8 (calprotectin)
- AQP8 (top downregulated)
- HMGCS2 (ketogenesis)
- SLC51A (bile acid transporter)
- TRIM29 (epithelial stress)

For validation priorities:
1. SLC6A14 - biomarker/therapeutic target (UC biomarker)
2. DUOX2/DUOXA2 - mechanistic (oxidative stress)
3. CXCL1/CXCL2/CXCL3 - CXCR2 axis therapeutic target
4. AQP8 loss - biomarker of colonocyte dysfunction
5. The transport/metabolic loss - confounding check (cell composition)

Important caveats:
- Tissue composition: UC mucosa has increased neutrophils and altered epithelial architecture. Many "upregulated" genes (CXCL1/2/3, S100A8, LCN2, CHI3L1) are neutrophil-derived. Many "downregulated" genes (AQP7, AQP8, HMGCS2, SLC16A1, MEP1B etc.) are mature colonocyte markers - their loss may reflect loss of mature differentiated cells rather than active suppression.
- No independent cohort replication available
- Treatment exposure (steroids, 5-ASA) may affect expression
- Disease severity matter

Let me write this up carefully.

For evidence grounding, I need to:
- Direct: uploaded FDR/log2FC
- Pathway/ontology: from retrieved GO/KEGG/Reactome (note: not new enrichment)
- Network: STRING, TRRUST, OmniPath
- Disease: GWAS, ClinVar, OpenTargets
- Tissue: GTEx, HPA
- Drug: ChEMBL, ClinicalTrials
- Literature: PubMed

Let me also note the Direct vs Indirect evidence:
- The uploaded table only contains the effect sizes and P-values
- The recurrent pathway/ontology modules are retrieved from external databases (Reactome, QuickGO) and reflect prior knowledge, not new computation
- No single-cell deconvolution was performed

Let me ensure I follow the policy:
- Don't call enrichment "validated" - only "supported by recurrent annotation"
- No independent cohort replication
- Note that pathway records are not "replication"

I'll structure the response following the requested sections. Let me draft it.

I should be careful about the locator: "PMCID:" or PMID references when citing. Let me use the PMIDs listed where relevant.

Now let me write the response.</think>

# Multidimensional Interpretation: Ulcerative Colitis vs. Healthy Control in Colonic Mucosa

## 1. Overall Biological Interpretation

The 100-gene signature behaves as a coherent two-arm readout of inflamed colonic mucosa in ulcerative colitis. The **up arm (40 genes)** is dominated by neutrophil/innate inflammation, antimicrobial/oxidative defense, tissue remodeling, and an immunoglobulin/plasma-cell signal. The **down arm (60 genes)** is dominated by mature colonocyte transporters, detoxifying/drug-metabolizing enzymes, ketogenic and gluconeogenic machinery, and mucin-type glycosylation enzymes. Taken together, the signature is consistent with active neutrophilic inflammation superimposed on loss of differentiated absorptive colonocyte identity, accompanied by epithelial remodeling and altered bile-acid/solute handling. No independent cohort statistic was supplied, so every claim below that is anchored to the uploaded table is supported by direct effect-size/FDR evidence, while external entries are contextual and are explicitly labeled as such.

---

## 2. Core Biological Programs (≤5)

### Program A — Neutrophil recruitment and IL-17/NF-κB-driven innate inflammation (UP)
**Direction:** upregulated in UC.
**Supporting genes:** CXCL1 (log2FC +3.46), CXCL2 (+2.80), CXCL3 (+2.33), CXCL8-cluster chemokines rather than CXCL8 itself; IL1RN (+2.88); SOCS3 (+2.79); IRAK3 (+1.78); MMP3 (+4.64); LCN2 (+2.67); CHI3L1 (+4.59); S100A8 (+3.80); VNN1 (+3.20); TIMP1 (+1.97).
**Pathway match:** KEGG *IL-17 signaling pathway*; Reactome *Interleukin-17 signaling*; Hallmark *TNFA_SIGNALING_VIA_NFKB*, *INFLAMMATORY_RESPONSE*.
**Why this is coherent:** CXCL1/2/3 are ELR+ CXC chemokines that act through CXCR2 to recruit neutrophils; CHI3L1, S100A8, LCN2, TIMP1, MMP3 are canonical neutrophil-derived products in the inflamed gut; IL1RN, SOCS3, and IRAK3 are NF-κB-induced negative-feedback regulators, i.e., inflammation-induced inflammation brakes. The retrieved network record (CXCR2 hub connecting CXCL1/2/3) is STRING co-membership, not regulatory or physical interaction.
**Strength and limitations:** Strength = multiple independent DEGs from the same axis, with the retrieved KEGG module aligning with the IL-17/chemokine program. Limitations = no enrichment P value was recomputed; some signals (S100A8, LCN2, CHI3L1) are heavily neutrophil-derived, so a fraction of the apparent "epithelial inflammation" may be composition.

### Program B — Epithelial antimicrobial/oxidative defense (UP)
**Direction:** upregulated.
**Supporting genes:** DUOX2 (+4.67), DUOXA2 (+2.89), PI3/elafin (+2.21), PLA2G2A (+1.53), REG4 (+2.05), S100P (+1.77), TRIM29 (+2.83), CD55 (+2.04), CTLA4 (+2.62), IFI16 (+1.39), IGHV4-31/IGHM/IGHG1/IGH (Ig transcripts, +1.89).
**Pathway match:** Reactome *DUOX2-mediated ROS production*, *Innate immune system*, *Antimicrobial peptides*; KEGG *IL-17 signaling pathway* (overlap with Program A).
**Why this is coherent:** DUOX2 and its maturation factor DUOXA2 are the principal H₂O₂-generating system of inflamed airway and colonic epithelia; PI3 (elafin) and PLA2G2A are barrier antimicrobial effectors; REG4 is a goblet/regenerative marker induced in IBD; TRIM29 and IFI16 are interferon/stress-response genes; the Ig-heavy-chain transcripts and CD55 (complement decay-accelerator) point to plasma-cell infiltration and complement regulation. These nodes are biologically linked but are not supported by a shared direct physical complex in the uploaded data.
**Strength and limitations:** Strong directionally concordant set; the IL-17/innate overlap with Program A is expected. Limitation: the IGH transcripts are likely a plasma-cell composition signal rather than a colonocyte program, and the antimicrobial/IL-17 KEGG module is a single retrieved record, not a recomputed enrichment.

### Program C — Loss of mature colonocyte absorptive/transport identity (DOWN)
**Direction:** downregulated.
**Supporting genes:** AQP7 (−2.32), AQP8 (−4.42), SLC16A1/MCT1 (−2.38), SLC51A/OSTα (−3.71), SLC38A4 (−3.07), SLC23A1 (−2.40), SLC23A3 (−1.93), SLC19A3 (−1.34), ABCG2 (−2.92), DEFB1 (−2.31), MEP1B (−2.99), GBA3 (−3.00), HMGCS2 (−3.45), G6PC (−1.52), B4GALNT2 (−1.79), GCNT2 (−1.55), GXYLT2 (−1.70), SCUBE2 (−1.64).
**Pathway match:** GO *Fluid Transport (GO:0042044)*, *Water Transport (GO:0006833)*, *Carboxylic Acid Transport (GO:0046942)*; KEGG *Bile secretion* (overlap with Program E).
**Why this is coherent:** AQP7/8, SLC16A1, SLC38A4, SLC23A1/3, SLC19A3, and ABCG2 form a coherent solute/water/electrolyte transport module; HMGCS2 and G6PC are ketogenic and gluconeogenic colonocyte enzymes; B4GALNT2, GCNT2, GXYLT2 are mucin-type glycosyltransferases that set the colonocyte glycocalyx/MUC2 O-glycan profile; DEFB1 is a colonocyte-derived antimicrobial peptide. The retrieved GO modules (fluid/water/carboxylic acid transport) are annotation-level supporting evidence, not a new pathway test.
**Strength and limitations:** Strong coordinated downregulation across multiple independent solute-handling genes. Key limitation: this signature overlaps with the transcriptomic identity of differentiated surface colonocytes, so part of the signal may reflect loss of mature cells rather than active suppression. Network edges (AQP7–AQP8 via AQP11/AQP12A in STRING) are co-expression/co-membership, not direct binding.

### Program D — Tissue remodeling, wound healing, and partial EMT (UP)
**Direction:** upregulated.
**Supporting genes:** PRRX1 (+2.91), TNC (+2.58), CDH3 (+2.29), PDPN (+2.54), FILIP1L (+1.86), TGM2 (+1.91), SERPINB5 (+3.29), MMP3 (+4.64), IGDCC4 (+1.86).
**Pathway match:** Hallmark *EPITHELIAL_MESENCHYMAL_TRANSITION*, *ANGIOGENESIS*; Reactome *Extracellular matrix organization*.
**Why this is coherent:** PRRX1 is a master EMT transcription factor; CDH3 (P-cadherin) replaces CDH1/E-cadherin in wound-associated and reparative epithelial states; TNC, TGM2, PDPN, FILIP1L, and SERPINB5 are stromal/remodeling effectors; MMP3 is both inflammatory and matrix-degrading. The STRING CDH1–CDH3–S100A8 edge is co-membership, not direct physical interaction.
**Strength and limitations:** Biologically tight set; independent of Programs A and B in mechanism. Limitation: remodeling signatures overlap with stromal-cell contamination, so single-cell validation is needed.

### Program E — Loss of bile-acid, lipid, and xenobiotic handling (DOWN)
**Direction:** downregulated.
**Supporting genes:** SLC51A/OSTα (−3.71), ABCG2/BCRP (−2.92), ABCB11/BSEP (−1.15), HMGCS2 (−3.45), CYP2B6 (−2.78), CYP2B7P (−2.72), LIPC (−1.57), HSD3B2 (−2.77), ACSF2 (−1.93), TAT (−1.19), NAT8B/NAT8 (−1.31).
**Pathway match:** KEGG *Bile secretion*; Reactome *Phase I functionalization of compounds*, *Bile acid and bile salt metabolism*.
**Why this is coherent:** These genes jointly define the apical bile-acid efflux and xenobiotic-metabolizing machinery of differentiated colonocytes (OSTα/OSTβ, BSEP, BCRP, CYP2B6, HSD3B2). Their coordinated loss is consistent with impaired enterocyte barrier metabolism and dysregulated luminal bile-acid exposure — a recognized feature of UC pathophysiology.
**Strength and limitations:** Coherent and supported by the KEGG *Bile secretion* retrieved record. Limitation: the OS gene family has overlap with hepatocyte contamination; in colonic mucosa the relevant compartment is the epithelial cell, and assumption-free deconvolution was not performed.

> *Note on redundancy:* Programs A and B share IL-17/NF-κB drivers and several nodes; they are kept separate because A emphasizes the neutrophil chemokine axis and B emphasizes epithelial antimicrobial/oxidative and plasma-cell effectors. Programs C and E share colonocyte identity but are kept separate because C is mainly transport/homeostasis and E is mainly bile-acid/drug metabolism.

---

## 3. Key Genes and Interaction Modules (≤10)

For each, the "statistical direction" is taken directly from the uploaded table.

1. **CXCL1 / CXCL2 / CXCL3 (UP; +3.46, +2.80, +2.33)** — Core of Program A. Network evidence: STRING co-membership/functional association at CXCR2 (selected-gene-count 3). This is **co-expression / pathway co-membership**, not a direct physical interaction. The CXCL1/2/3–CXCR2 axis is a canonical UC susceptibility locus (GWAS, retrieved).

2. **MMP3 (UP; +4.64)** — Matrix metalloproteinase at the intersection of Programs A and D. STRING co-membership with CDH1/S100A8 is **pathway co-membership**, not direct binding. A known UC biomarker candidate (literature).

3. **CHI3L1 (UP; +4.59)** — Macrophage/neutrophil chitinase-like protein; clinical biomarker candidate in IBD (literature; Europe PMC 41029776 indirectly supports biomarker-discovery efforts).

4. **S100A8 (UP; +3.80)** and **LCN2 (UP; +2.67)** — Calprotectin and neutrophil gelatinase-associated lipocalin; widely used fecal biomarkers. STRING CDH1–S100A8 edge is pathway co-membership only.

5. **DUOX2 (UP; +4.67) / DUOXA2 (UP; +2.89)** — H₂O₂-generating epithelial oxidase machinery, mature/functional interaction (DUOXA2 is the maturation factor of DUOX2). This is the **closest direct physical/functional relationship in the dataset**, supported by Reactome pathways.

6. **SOCS3 (UP; +2.79) / IRAK3 (UP; +1.78) / IL1RN (UP; +2.88)** — NF-κB-negative-feedback regulators. TRRUST regulatory interactions for SOCS3 are listed in the evidence pack (regulatory interaction, not physical binding).

7. **AQP8 (DOWN; −4.42) / AQP7 (DOWN; −2.32)** — Core of Program C. STRING link through AQP11/AQP12A is co-membership, not direct binding. AQP8 is a well-known colonocyte marker whose loss mirrors loss of mature surface colonocytes.

8. **HMGCS2 (DOWN; −3.45)** — Mitochondrial ketogenic enzyme; a robust marker of differentiated colonocytes. Its loss supports the colonocyte-identity collapse interpretation in Program C.

9. **SLC51A/OSTα (DOWN; −3.71) / ABCG2 (DOWN; −2.92) / ABCB11 (DOWN; −1.15)** — Core of Program E; the apical bile-acid and xenobiotic efflux triad. STRING and Reactome provide co-membership and pathway evidence; physical interaction evidence is not asserted here.

10. **TRIM29 (UP; +2.83) / TGM2 (UP; +1.91) / PRRX1 (UP; +2.91) / CDH3 (UP; +2.29)** — The remodel/EMT node (Program D). STRING CDH1–CDH3 is **pathway co-membership**, not direct binding; PRRX1 is a transcription factor, so its relationship to CDH3 is **regulatory**, not physical.

**Relationship-class summary:** The only bona fide physical/functional interaction in the cohort is the DUOX2–DUOXA2 maturation pair. Most other "interactions" mentioned in the network record are STRING co-membership/co-expression or Reactome pathway co-membership, and should not be cited as direct physical binding.

---

## 4. Validation Priorities (≤5)

### Priority 1 — DUOX2/DUOXA2 as a mechanistic oxidative-stress driver (Mechanistic hypothesis)
- **Why prioritize:** They are the top-ranked antioxidant/oxidative-defense module whose protein products are known to be functionally coupled (DUOXA2 is the maturation factor of DUOX2). Their transcript-level co-upregulation is the strongest internal evidence of a coordinated epithelial program.
- **Dataset evidence:** DUOX2 +4.67 (FDR 4.4e-26), DUOXA2 +2.89 (FDR 1.1e-10).
- **External evidence:** Reactome *DUOX2-mediated ROS production* (annotation support); numerous PubMed records on DUOX2 in colitis epithelium.
- **Next step:** Quantify H₂O₂ in mucosal explants; siRNA/shRNA knockdown of DUOXA2 in colonic organoids to test whether DUOX2 protein levels and ROS production collapse together.
- **Status:** **Supported hypothesis** (mechanistic plausibility is strong, but causation in UC has not been demonstrated in this dataset).

### Priority 2 — CXCL1/2/3–CXCR2 axis as a therapeutic target (Therapeutic target)
- **Why prioritize:** Three members of the same chemokine cluster are all significantly upregulated, and the STRING hub is CXCR2.
- **Dataset evidence:** CXCL1 +3.46, CXCL2 +2.80, CXCL3 +2.33; all FDR < 1e-10.
- **External evidence:** KEGG *IL-17 signaling pathway*; literature on CXCR2 antagonism in IBD models; GWAS support for the IL-17/IL-23 axis in IBD.
- **Next step:** Stratify UC biopsies by neutrophilic infiltrate (MPO IHC) and check whether CXCL1/2/3 expression tracks neutrophil density independent of clinical severity; in parallel, evaluate CXCR2 antagonists in relevant preclinical colitis models.
- **Status:** **Supported hypothesis** (axis is biologically well established; whether blockade is clinically beneficial in UC is unresolved).

### Priority 3 — Loss of AQP8/HMGCS2/MCT1-positive mature colonocytes as a biomarker (Biomarker)
- **Why prioritize:** A coordinated collapse of multiple colonocyte-identity genes, with AQP8 the most strongly downregulated (−4.42).
- **Dataset evidence:** AQP8, HMGCS2, SLC16A1, MEP1B, GBA3, SLC51A, ABCG2 all FDR < 1e-13.
- **External evidence:** GO *Fluid/Water/Carboxylic Acid Transport*; PubMed 25171508 implicates loss of BRINP3 / colonocyte programs in UC.
- **Next step:** Single-cell RNA-seq or spatial transcriptomics to determine whether the loss is transcriptome-wide per cell or driven by loss of a mature colonocyte subpopulation; correlate with histology (crypt architecture).
- **Status:** **Exploratory hypothesis** as a biomarker; established that these are colonocyte markers.

### Priority 4 — Bile-acid and xenobiotic metabolism collapse (Mechanistic / interaction hypothesis)
- **Why prioritize:** Coordinated loss of SLC51A, ABCG2, ABCB11, CYP2B6, HSD3B2 suggests a definite metabolic vulnerability that may be therapeutically addressable.
- **Dataset evidence:** SLC51A −3.71, ABCG2 −2.92, ABCB11 −1.15, CYP2B6 −2.78, HSD3B2 −2.77.
- **External evidence:** KEGG *Bile secretion*; evidence from OpenTargets/ChEMBL for these as drug targets in other contexts.
- **Next step:** Measure luminal bile-acid composition in UC vs control and integrate with the colonocyte transcript signature; functionally test OSTα/OSTβ in colonic organoids.
- **Status:** **Supported hypothesis** (mechanism is plausible); causality in UC not established.

### Priority 5 — Tissue-composition / confounding check (Confounding or composition check)
- **Why prioritize:** Many "up" genes (CXCL1/2/3, S100A8, LCN2, CHI3L1, Ig transcripts) are myeloid or plasma-cell-derived; many "down" genes (AQP7/8, HMGCS2, SLC16A1, MEP1B, G6PC) are differentiated colonocyte markers. Both directions could partly reflect cell-mixture shifts rather than per-cell transcriptional changes.
- **Dataset evidence:** Indirect — directional asymmetry of lineages across the gene list.
- **External evidence:** Standard single-cell and deconvolution studies of UC mucosa show neutrophil expansion and loss of mature colonocytes.
- **Next step:** Deconvolution (e.g., MCP-counter, CIBERSORTx, or single-cell reference) or laser-capture microdissection + bulk RNA-seq to disentangle composition from per-cell regulation.
- **Status:** **Established evidence** that composition matters in UC; the specific decomposition into per-cell vs compositional change is **exploratory** for this dataset.

---

## 5. Evidence Grounding

- **Direct evidence (this dataset):** every effect size, direction, P, and FDR quoted above is from the uploaded table. All 100 genes have FDR ≤ 0.01.
- **Pathway/ontology evidence:** GO fluid transport, water transport, carboxylic acid transport; KEGG IL-17 signaling, bile secretion; Reactome DUOX2, complement, antimicrobial peptides. These are context only — they are retrieved annotations, not new tests performed on the data.
- **Network evidence:** STRING (CXCR2, ITGB1, CDH1, AOX1, AQP11/12A, CCL11 hubs), TRRUST (SOCS3 regulatory edges), OmniPath (ADRA2A). All such edges are co-expression, co-membership, or curated regulatory relationships unless explicitly stated otherwise; they are not direct physical binding unless so labeled (DUOX2/DUOXA2).
- **Disease-association evidence:** GWAS (100/100 selected items returned), OpenTargets (92/100), ClinVar (90/100). These are database-level associations, not replication.
- **Tissue/expression evidence:** GTEx (91/100), HPA (85/100) provide baseline tissue expression; relevant for ruling out tissue-confounded genes (e.g., CYP2B6, HSD3B2 have hepatic expression).
- **Drug/therapeutic evidence:** ChEMBL (40/100 partial), ClinicalTrials (51/100). Existence of a drug target is not therapeutic evidence for UC.
- **Literature evidence:** PubMed 41029776 (UC biomarker discovery), 25171508 (BRINP3 in UC), 38059894 (UC treatment response). These are supporting literature, not independent replication.
- **Independence note:** Many of these sources (GWAS, OpenTargets, ClinVar, literature) draw on overlapping IBD/UC GWAS catalogs. They are not independent replications, and pathway recurrence is not a P value; no new enrichment was performed and no independent cohort statistic was supplied.

---

## 6. Limitations and Alternative Explanations

1. **Tissue / cell-composition differences.** The strongest "up" genes (CXCL1/2/3, S100A8, LCN2, CHI3L1, Ig heavy chains) are largely neutrophil- and plasma-cell-derived; the strongest "down" genes (AQP7/8, HMGCS2, SLC16A1, MEP1B, G6PC) are mature colonocyte markers. Part of the signal is therefore architectural rather than regulatory. This can be tested by deconvolution, single-cell RNA-seq, or laser-capture microdissection (Priority 5).

2. **Disease severity and treatment exposure.** Many UC patients are on 5-ASA, corticosteroids, or biologics at the time of biopsy. The signature could be confounded by treatment rather than disease activity. Without per-sample clinical metadata, this cannot be ruled out; replication in a treatment-naïve cohort, or a severity-stratified analysis, is needed.

3. **Platform / batch effects.** The duplicated probes (rows=2–7 in the ledger) and probe IDs (PROBE_241592_PM_at, PROBE_227140_PM_at, PROBE_235105_PM_at) indicate a microarray dataset. Cross-platform concordance with RNA-seq would strengthen any conclusion.

4. **Association vs causation.** The data are cross-sectional. Whether the up-arm (chemokines, DUOX2, MMP3) drives epithelial damage or is a consequence of barrier breach cannot be resolved from this cohort. Only intervention studies (genetic deletion, neutralizing antibodies, organoid perturbations) can establish causation.

5. **Broad / non-specific pathway enrichment.** Chemokine and IL-17/NF-κB programs are activated in many inflammatory conditions, not only UC. As Program A and B are highly non-specific, their value lies in magnitude and coordinated direction (CXCL1/2/3 + DUOX2/DUOXA2 + MMP3), not in uniqueness. Programs C and E (loss of colonocyte identity and bile-acid metabolism) are more disease-informative for UC as a *colonic* disease.

---

**Bottom line.** The signature is a plausible UC-active-mucosa signature dominated by (i) neutrophilic/IL-17 innate inflammation, (ii) epithelial oxidative/antimicrobial defense, (iii) loss of colonocyte transport and metabolic identity, (iv) tissue-remodeling/EMT, and (v) loss of bile-acid/xenobiotic handling. Higher-confidence interpretations are Programs A, B, and C because they are supported by multiple independent genes with strong effect sizes. Programs D and E are well-supported but smaller in gene count. No independent cohort replication was performed, the GO/KEGG/Reactome modules are retrieved annotations rather than new enrichment tests, and tissue composition is a substantial confounder that should be addressed before any per-cell causal claim is made.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=3, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 94/100 selected items (records returned); cbioportal 87/100 selected items (records returned); chembl 40/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 51/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 55/100 selected items (partially returned; some queries failed); europepmc 936 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 91/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 85/100 selected items (records returned); humanbase 87/100 selected items (records returned); intact 85/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 45/100 selected items (records returned); opentargets 92/100 selected items (records returned); pubmed 750 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 87/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 88/100 selected items (records returned)
Local databases: gutmgene 8/100 selected items (records returned); hmdb 46/100 selected items (records returned); string 85/100 selected items (records returned); trrust 31/100 selected items (records returned)
